Jeremiah Hilkiah Wijaya1, Yang Yang Endro Arjuna2, Julius July2,3. 1. Department of Medicine, Universitas Pelita Harapan, Tangerang, Banten, Indonesia. jeremiah.hansum6@gmail.com. 2. Department of Medicine, Universitas Pelita Harapan, Tangerang, Banten, Indonesia. 3. Department of Neurosurgery, Universitas Pelita Harapan, Tangerang, Banten, Indonesia.
Abstract
PURPOSE: Petroclival meningioma (PM) is a challenging neuro oncology case and stereotactic radiosurgery (SRS) is proposed as one treatment option. This systematic review aimed to examine the role of SRS in treating PM cases. METHODS: We constructed a systematic review using the PRISMA guidelines using peer-reviewed English literature until 16 February 2022 from EuroPMC and PubMed. We used the terms petroclival meningioma, clival meningioma, apex petrous meningioma, spheno petroclival meningioma, stereotactic radiosurgery, radiosurgery, CyberKnife, Gamma Knife, linear accelerator, LINAC, and radiotherapy. RESULTS: 10 out of 266 studies were chosen for this systematic review, two of which are case reports. The study comprised 719 patients, 73.7% of whom were female (n = 530) and had a median age of 56.99 years (18-90 years). At the time of diagnosis, the median tumor volume was 6.07 cm3 (0.13-64.9 cm3). The tumors were frequently located near the petroclival junction (83.6%, n = 598). Following SRS, the median follow-up was 64.52 months (3-252 months). 46.5% of 719 PMs exhibited a decrease in tumor size. 46% and 7.5% showed no change and increase in tumor volume, respectively. At the last radiographic follow-up (7-21.2 years), tumor control with a median of 98.8% (85-100%). Complications occurred in 6% of patients, with hydrocephalus (2.2%) as the prevalent complication. The use of SRS as a primary treatment for petroclival cases was not associated with increased complication rate RR 0.62 (95% CI [0.11, 3.59], p = 0.59) but statistically correlated with clinical failure clinical failure RR 0.56 (95% CI [0.32, 0.98], p = 0.04). CONCLUSIONS: We found a low number of complications following SRS intervention and has been effectively controlling tumor progression.
PURPOSE: Petroclival meningioma (PM) is a challenging neuro oncology case and stereotactic radiosurgery (SRS) is proposed as one treatment option. This systematic review aimed to examine the role of SRS in treating PM cases. METHODS: We constructed a systematic review using the PRISMA guidelines using peer-reviewed English literature until 16 February 2022 from EuroPMC and PubMed. We used the terms petroclival meningioma, clival meningioma, apex petrous meningioma, spheno petroclival meningioma, stereotactic radiosurgery, radiosurgery, CyberKnife, Gamma Knife, linear accelerator, LINAC, and radiotherapy. RESULTS: 10 out of 266 studies were chosen for this systematic review, two of which are case reports. The study comprised 719 patients, 73.7% of whom were female (n = 530) and had a median age of 56.99 years (18-90 years). At the time of diagnosis, the median tumor volume was 6.07 cm3 (0.13-64.9 cm3). The tumors were frequently located near the petroclival junction (83.6%, n = 598). Following SRS, the median follow-up was 64.52 months (3-252 months). 46.5% of 719 PMs exhibited a decrease in tumor size. 46% and 7.5% showed no change and increase in tumor volume, respectively. At the last radiographic follow-up (7-21.2 years), tumor control with a median of 98.8% (85-100%). Complications occurred in 6% of patients, with hydrocephalus (2.2%) as the prevalent complication. The use of SRS as a primary treatment for petroclival cases was not associated with increased complication rate RR 0.62 (95% CI [0.11, 3.59], p = 0.59) but statistically correlated with clinical failure clinical failure RR 0.56 (95% CI [0.32, 0.98], p = 0.04). CONCLUSIONS: We found a low number of complications following SRS intervention and has been effectively controlling tumor progression.
Authors: Hideyuki Kano; Nasir R Awan; Thomas J Flannery; Aditya Iyer; John C Flickinger; L Dade Lunsford; Douglas Kondziolka Journal: Stereotact Funct Neurosurg Date: 2010-12-01 Impact factor: 1.875
Authors: Jeannie Han; Michael R Girvigian; Joseph C T Chen; Michael J Miller; Kenneth Lodin; Javad Rahimian; Alonzo Arellano; Benjamin L Cahan; John S Kaptein Journal: Am J Clin Oncol Date: 2014-06 Impact factor: 2.339
Authors: Thomas J Flannery; Hideyuki Kano; L Dade Lunsford; Sait Sirin; Matthew Tormenti; Ajay Niranjan; John C Flickinger; Douglas Kondziolka Journal: J Neurosurg Date: 2010-05 Impact factor: 5.115
Authors: Douglas Kondziolka; David Mathieu; L Dade Lunsford; Juan J Martin; Ricky Madhok; Ajay Niranjan; John C Flickinger Journal: Neurosurgery Date: 2008-01 Impact factor: 4.654